Table 3. Current risk stratification... | American Society of Hematology

Table 3.

Current risk stratification systems in ET

IPSET (revised)³⁰		MIPSS-ET³¹		MPN personalized risk calculator⁴
IPSET (revised)³⁰		Factor	Points∗	MPN personalized risk calculator⁴
Very low	No prior thrombosis + age ≤60 y + JAK2-unmutated	Adverse mutation†	2	Available genomic data plus clinical factors (age, Hb, WBC, plts, sex, prior thrombosis, splenomegaly)
Low	No prior thrombosis + age ≤ 60 y + JAK2-mutated	Age > 60 y	3
Intermediate	No thrombosis + age >60 y + JAK2-unmutated	Male sex	1
High	Thrombosis history (any age / genotype), or age >60 y + JAK2-mutated	WBC ≥11 × 10⁹/L	1

IPSET (revised)³⁰		MIPSS-ET³¹		MPN personalized risk calculator⁴
IPSET (revised)³⁰		Factor	Points∗	MPN personalized risk calculator⁴
Very low	No prior thrombosis + age ≤60 y + JAK2-unmutated	Adverse mutation†	2	Available genomic data plus clinical factors (age, Hb, WBC, plts, sex, prior thrombosis, splenomegaly)
Low	No prior thrombosis + age ≤ 60 y + JAK2-mutated	Age > 60 y	3
Intermediate	No thrombosis + age >60 y + JAK2-unmutated	Male sex	1
High	Thrombosis history (any age / genotype), or age >60 y + JAK2-mutated	WBC ≥11 × 10⁹/L	1

Hb, hemoglobin; MIPSS-ET, Mutation-Enhanced International Prognostic Systems for ET; Plts, platelets; WBC, white blood cell count.

Total score: 0 to 1, low risk; 2 to 5, intermediate risk; ≥6, high risk.

SRSF2/SF3B1/U2AF1/TP53.